Bortezomib effect on E2F and cyclin family members in human hepatocellular carcinoma cell lines

World Journal of Gastroenterology

Volumn 20, Issue 3, 2014, Pages 795-803

  Baiz, Daniele ^a,b   Dapas, Barbara ^a   Farra, Rossella ^a   Scaggiante, Bruna ^a   Pozzato, Gabriele ^c   Zanconati, Fabrizio ^c   Fiotti, Nicola ^c   Consoloni, Lara ^c   Chiaretti, Sara ^a   Grassi, Gabriele ^a,c  

^a UNIVERSITY OF TRIESTE   (Italy)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TRIESTE   (Italy)

Author keywords

26S proteasome; Bortezomib; Cyclins; E2F family; Hepatocellular carcinoma; Liver; Microarray

Indexed keywords

BORTEZOMIB; CYCLIN DEPENDENT KINASE; CYCLINE; MESSENGER RNA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR E2F2; TRANSCRIPTION FACTOR E2F3; TRANSCRIPTION FACTOR E2F4; TRANSCRIPTION FACTOR E2F5; TRANSCRIPTION FACTOR E2F6; TRANSCRIPTION FACTOR E2F7; TRANSCRIPTION FACTOR E2F8; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DNA MICROARRAY; EPITHELIAL MESENCHYMAL TRANSITION; GENE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MICROARRAY ANALYSIS; MICROARRAY KIT; NUCLEOTIDE SEQUENCE; PHENOTYPE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION;

26S PROTEASOME; BORTEZOMIB; CYCLINS; E2F FAMILY; HEPATOCELLULAR CARCINOMA; LIVER; MICROARRAY;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CYCLINS; E2F TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; PHENOTYPE; PROTEASOME INHIBITORS; PYRAZINES; RNA INTERFERENCE; RNA, MESSENGER; TRANSFECTION;

EID: 84892876981     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i3.795     Document Type: Article

References (33)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576 [PMID: 17570226]
2. Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 2010; 42 Suppl 3: S206-S214 [PMID: 20547305 DOI: 10.1016/S1590-8658(10)60507-5]
3. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-1127 [PMID: 21992124 DOI: 10.1056/NEJMra1001683]
4. European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-943 [PMID: 22424438 DOI: 10.1016/j.jhep.2011.12.001]
5. Colombo M. Multidisciplinary approach to hepatocellular carcinoma. Preface. Dig Liver Dis 2010; 42 Suppl 3: S205 [PMID: 20547304 DOI: 10.1016/S1590-8658(10)00205-7]
6. Shin JW, Chung YH. Molecular targeted therapy for hepatocellular carcinoma: current and future. World J Gastroenterol 2013; 19: 6144-6155 [PMID: 24115810]
7. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390 [PMID: 18650514 DOI: 10.1056/NEJMoa0708857]
8. Zavrski I, Jakob C, Schmid P, Krebbel H, Kaiser M, Fleissner C, Rosche M, Possinger K, Sezer O. Proteasome: an emerging target for cancer therapy. Anticancer Drugs 2005; 16: 475-481 [PMID: 15846112]
9. Kim GP, Mahoney MR, Szydlo D, Mok TS, Marshke R, Holen K, Picus J, Boyer M, Pitot HC, Rubin J, Philip PA, Nowak A, Wright JJ, Erlichman C. An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma. Invest New Drugs 2012; 30: 387-394 [PMID: 20839030 DOI: 10.1007/s10637-010-9532-1]
10. Wahl K, Siegemund M, Lehner F, Vondran F, Nüssler A, Länger F, Krech T, Kontermann R, Manns MP, Schulze-Osthoff K, Pfizenmaier K, Bantel H. Increased apoptosis induction in hepatocellular carcinoma by a novel tumor-targeted TRAIL fusion protein combined with bortezomib. Hepatology 2013; 57: 625-636 [PMID: 22991197 DOI: 10.1002/hep.26082]
11. Saeki I, Terai S, Fujisawa K, Takami T, Yamamoto N, Matsumoto T, Hirose Y, Murata Y, Yamasaki T, Sakaida I. Bortezomib induces tumor-specific cell death and growth inhibition in hepatocellular carcinoma and improves liver fibrosis. J Gastroenterol 2013; 48: 738-750 [PMID: 23011081 DOI: 10.1007/s00535-012-0675-z]
12. Wang C, Gao D, Guo K, Kang X, Jiang K, Sun C, Li Y, Sun L, Shu H, Jin G, Sun H, Wu W, Liu Y. Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model. BMC Cancer 2012; 12: 166 [PMID: 22559167 DOI: 10.1186/1471-2407-12-166]
13. Ko BS, Chang TC, Chen CH, Liu CC, Kuo CC, Hsu C, Shen YC, Shen TL, Golubovskaya VM, Chang CC, Shyue SK, Liou JY. Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B. Life Sci 2010; 86: 199-206 [PMID: 20006625 DOI: 10.1016/j.lfs.2009.12.003]
14. Hui B, Shi YH, Ding ZB, Zhou J, Gu CY, Peng YF, Yang H, Liu WR, Shi GM, Fan J. Proteasome inhibitor interacts synergistically with autophagy inhibitor to suppress proliferation and induce apoptosis in hepatocellular carcinoma. Cancer 2012; 118: 5560-5571 [PMID: 22517429 DOI: 10.1002/ cncr.27586]
15. Chen KF, Liu CY, Lin YC, Yu HC, Liu TH, Hou DR, Chen PJ, Cheng AL. CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells. Oncogene 2010; 29: 6257-6266 [PMID: 20729919 DOI: 10.1038/onc.2010.357]
16. Chen KF, Yu HC, Liu TH, Lee SS, Chen PJ, Cheng AL. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation. J Hepatol 2010; 52: 88-95 [PMID: 19913321 DOI: 10.1016/j.jhep.2009.10.011]
17. Chen KF, Yeh PY, Yeh KH, Lu YS, Huang SY, Cheng AL. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res 2008; 68: 6698-6707 [PMID: 18701494 DOI: 10.1158/0008-5472.CAN-08-0257]
18. Yu HC, Hou DR, Liu CY, Lin CS, Shiau CW, Cheng AL, Chen KF. Cancerous inhibitor of protein phosphatase 2A mediates bortezomib-induced autophagy in hepatocellular carcinoma independent of proteasome. PLoS One 2013; 8: e55705 [PMID: 23383345 DOI: 10.1371/journal.pone.0055705]
19. Spratlin JL, Pitts TM, Kulikowski GN, Morelli MP, Tentler JJ, Serkova NJ, Eckhardt SG. Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines. Anticancer Res 2011; 31: 1093-1103 [PMID: 21508352]
20. Baiz D, Pozzato G, Dapas B, Farra R, Scaggiante B, Grassi M, Uxa L, Giansante C, Zennaro C, Guarnieri G, Grassi G. Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels. Biochimie 2009; 91: 373-382 [PMID: 19041685 DOI: 10.1016/j.biochi.2008.10.015]
21. Attwooll C, Lazzerini Denchi E, Helin K. The E2F family: specific functions and overlapping interests. EMBO J 2004; 23: 4709-4716 [PMID: 15538380]
22. Sun HX, Xu Y, Yang XR, Wang WM, Bai H, Shi RY, Nayar SK, Devbhandari RP, He YZ, Zhu QF, Sun YF, Hu B, Khan M, Anders RA, Fan J. Hypoxia inducible factor 2 alpha inhibits hepatocellular carcinoma growth through the transcription factor dimerization partner 3/ E2F transcription factor 1-dependent apoptotic pathway. Hepatology 2013; 57: 1088-1097 [PMID: 23212661 DOI: 10.1002/hep.26188]
23. Chen YL, Uen YH, Li CF, Horng KC, Chen LR, Wu WR, Tseng HY, Huang HY, Wu LC, Shiue YL. The E2F transcription factor 1 transactives stathmin 1 in hepatocellular carcinoma. Ann Surg Oncol 2013; 20: 4041-4054 [PMID: 22911364]
24. Farra R, Dapas B, Pozzato G, Scaggiante B, Agostini F, Zennaro C, Grassi M, Rosso N, Giansante C, Fiotti N, Grassi G. Effects of E2F1-cyclin E1-E2 circuit down regulation in hepatocellular carcinoma cells. Dig Liver Dis 2011; 43: 1006-1014 [PMID: 21831731 DOI: 10.1016/j.dld.2011.07.007]
25. Xu T, Zhu Y, Xiong Y, Ge YY, Yun JP, Zhuang SM. MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. Hepatology 2009; 50: 113-121 [PMID: 19441017 DOI: 10.1002/hep.22919]
26. Deng Q, Wang Q, Zong WY, Zheng DL, Wen YX, Wang KS, Teng XM, Zhang X, Huang J, Han ZG. E2F8 contributes to human hepatocellular carcinoma via regulating cell proliferation. Cancer Res 2010; 70: 782-791 [PMID: 20068156 DOI: 10.1158/0008-5472.CAN-09-3082]
27. Xiao F, Zhang W, Chen L, Chen F, Xie H, Xing C, Yu X, Ding S, Chen K, Guo H, Cheng J, Zheng S, Zhou L. MicroRNA-503 inhibits the G1/S transition by downregulating cyclin D3 and E2F3 in hepatocellular carcinoma. J Transl Med 2013; 11: 195 [PMID: 23967867 DOI: 10.1186/1479-5876-11-195]
28. Jiang Y, Yim SH, Xu HD, Jung SH, Yang SY, Hu HJ, Jung CK, Chung YJ. A potential oncogenic role of the commonly observed E2F5 overexpression in hepatocellular carcinoma. World J Gastroenterol 2011; 17: 470-477 [PMID: 21274376 DOI: 10.3748/wjg.v17.i4.470]
29. Grassi G, Scaggiante B, Farra R, Dapas B, Agostini F, Baiz D, Rosso N, Tiribelli C. The expression levels of the translational factors eEF1A 1/2 correlate with cell growth but not apoptosis in hepatocellular carcinoma cell lines with different differentiation grade. Biochimie 2007; 89: 1544-1552 [PMID: 17825975]
30. Knowles BB, Howe CC, Aden DP. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 1980; 209: 497-499 [PMID: 6248960]
31. Fujise K, Nagamori S, Hasumura S, Homma S, Sujino H, Matsuura T, Shimizu K, Niiya M, Kameda H, Fujita K. Integration of hepatitis B virus DNA into cells of six established human hepatocellular carcinoma cell lines. Hepatogastroenterology 1990; 37: 457-460 [PMID: 1701409]
32. Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, Logothetis CJ. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004; 22: 2108-2121 [PMID: 15169797]
33. Palaiologou M, Koskinas J, Karanikolas M, Fatourou E, Tiniakos DG. E2F-1 is overexpressed and pro-apoptotic in human hepatocellular carcinoma. Virchows Arch 2012; 460: 439-446 [PMID: 22450712 DOI: 10.1007/s00428-012-1220-4]